Zobrazeno 1 - 10
of 81
pro vyhledávání: '"11"'
Autor:
Michele Connelly, Jia Xie, Nathaniel R. Twarog, Natasha Sahr, Jessica Gartrell, Hyekyung P. Cho, Anang A. Shelat, Sara M. Federico, Kaley Blankenship, Marcia Mellado-Largarde, Jiyang Yu, Christopher L. Tinkle, Geoffrey Neale, Elizabeth Stewart, Lauren Hoffmann, Koon-Kiu Yan, Armita Bahrami, Shondra M. Pruett-Miller, April Sykes, Michael R. Clay, Shaina N. Porter
Publikováno v:
Mol Cancer Ther
Pediatric sarcomas represent a heterogeneous group of malignancies that exhibit variable response to DNA-damaging chemotherapy. Schlafen family member 11 protein (SLFN11) increases sensitivity to replicative stress and has been implicated as a potent
Autor:
Fen Liu, Jia Yu Wang, Chun Yan Wang, Xu Guang Yan, Su Tang Guo, Chen Chen Jiang, Lei Jin, Hamed Yari, Yuan Yuan Zhang, Xudong Zhang
Publikováno v:
Molecular Cancer Therapeutics. 15:448-459
Oncogenic mutations of KRAS pose a great challenge in the treatment of colorectal cancer. Here we report that mutant KRAS colon cancer cells are nevertheless more susceptible to apoptosis induced by the HSP90 inhibitor AUY922 than those carrying wild
Autor:
Wei, Jun, Kitada, Shinichi, Rega, Michele F., Emdadi, Aras, Yuan, Hongbin, Cellitti, Jason, Stebbins, John L., Zhai, Dayong, Sun, Jiazhi, Yang, Li, Dahl, Russell, Zhang, Ziming, Wu, Bainan, Wang, Si, Reed, Tyler A., Wang, Hong-Gang, Lawrence, Nicholas, Sebti, Said, Reed, John C., Pellecchia, Maurizio
Publikováno v:
Molecular Cancer Therapeutics. 8:904-913
Guided by a combination of nuclear magnetic resonance binding assays and computational docking studies, we synthesized a library of 5,5′ substituted Apogossypol derivatives as potent Bcl-XL antagonists. Each compound was subsequently tested for its
Autor:
Jerry M. Adams, Malti Nikrad, Andrew S. Kraft, Thomas R Johnson, Hamsa Puthalalath, Leigh Coultas
Publikováno v:
Molecular Cancer Therapeutics. 4:443-449
Previously, we showed that the proteasome inhibitor bortezomib/Velcade (formerly PS-341) synergizes with the protein tumor necrosis factor α–related apoptosis-inducing ligand (TRAIL), a ligand for certain death receptors, to induce apoptosis in ce
Publikováno v:
Molecular cancer therapeutics, 11(11), 2419-2428. AMER ASSOC CANCER RESEARCH
Molecular cancer therapeutics, 11(11), 2419-2428. American Association for Cancer Research Inc.
Molecular cancer therapeutics, 11(11), 2419-2428. American Association for Cancer Research Inc.
New approaches to block the function of tumor stromal cells such as cancer-associated fibroblasts and pericytes is an emerging field in cancer therapeutics as these cells play a crucial role in promoting angiogenesis and tumor growth via paracrine si
Autor:
Sétha Douc-Rasy, Eric Nguyen, Mona Samy, Jean Bénard, Josette Hillion, Charles-Henry Gattolliat, Frédéric Pendino, Sophie Bombard, Evelyne Ségal-Bendirdjian
Publikováno v:
Molecular Cancer Therapeutics. 11:2384-2393
Telomerase, a ribonucleoprotein complex mainly composed of the reverse transcriptase catalytic subunit (human telomerase reverse transcriptase, hTERT) and the RNA component (hTR), is a key enzyme of cancer progression. That aggressive stage 4-neurobl
Publikováno v:
Molecular Cancer Therapeutics. 11:2410-2418
Almost all patients with advanced prostate cancer progress to castration-resistant stage with limited treatment options. Oncolytic adenoviruses have been actively pursued as potential agents for cancer treatment. Virtually all clinical trials on onco
Autor:
Marc Ladanyi, Mark G. Kris, Maria E. Arcila, Gregory J. Riely, Maureen F. Zakowski, Valerie W. Rusch, M. Catherine Pietanza, Camelia S. Sima, Christopher Lau, Paul K. Paik, Jamie E. Chaft
Publikováno v:
Molecular Cancer Therapeutics. 11:485-491
Phosphoinositide-3-kinase catalytic alpha polypeptide (PIK3CA) encodes the p110α subunit of the mitogenic signaling protein phosphoinositide 3-kinase (PI3K). PIK3CA mutations in the helical binding domain and the catalytic subunit of the protein hav
Autor:
Filip Janku, John W. Moroney, Siqing Fu, Sarina Anne Piha-Paul, Ignacio Garrido-Laguna, Rajyalakshmi Luthra, Aung Naing, David S. Hong, Xuemei Wang, Apostolia Maria Tsimberidou, Jennifer J. Wheler, Razelle Kurzrock, Stacy L. Moulder, Gerald S. Falchook
Publikováno v:
Molecular Cancer Therapeutics. 10:558-565
Preclinical data suggest that PIK3CA mutations predict response to PI3K/AKT/mTOR inhibitors. Concomitant KRAS or BRAF mutations may mediate resistance. Therefore, tumors from patients referred to the phase I program for targeted therapy starting in O
Publikováno v:
Molecular cancer therapeutics. 11(11)
Senescence, an inherent tumor suppressive mechanism, is a critical determinant for chemotherapy. In the present study, we show that the monocarboxylate transporter 2 (MCT2) protein was tumor-selectively expressed in human colorectal malignancies and